Skip to Main content Skip to Navigation
Journal articles

Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease

Abstract : Delayed hemolytic transfusion reaction (DHTR), a life-threatening transfusion complication in sickle cell disease (SCD), is characterized by a marked hemoglobin drop with destruction of both transfused and autologous red blood cells (RBCs) and exacerbation of SCD symptoms. One mechanism of RBCs destruction is auto-antibody production secondary to transfusion. As rituximab specifically targets circulating B cells, we thought that it could be beneficial in preventing this immune-mediated transfusion complication. We report the case of a SCD patient who previously experienced DHTR with auto-antibodies and who needed a new transfusion. DHTR recurrence was successfully prevented by rituximab administration prior transfusion, supporting the safe use of rituximab to prevent DHTR in SCD patients as a second line approach when other measures failed.
Complete list of metadata
Contributor : Philippe CHADEBECH Connect in order to contact the contributor
Submitted on : Friday, May 28, 2021 - 5:49:40 PM
Last modification on : Wednesday, October 20, 2021 - 3:22:13 AM
Long-term archiving on: : Sunday, August 29, 2021 - 7:45:49 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




F. Noizat-Pirenne, D. Bachir, P. Chadebech, M. Michel, A. Plonquet, et al.. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica, Ferrata Storti Foundation, 2007, 92 (12), pp.e132-e135. ⟨10.3324/haematol.12074⟩. ⟨inserm-03241610⟩



Record views